Takeda Pharmaceutical (NYSE:TAK) Releases FY 2026 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 3.009-3.009 for the period, compared to the consensus EPS estimate of 1.570. The company issued revenue guidance of $29.6 billion-$29.6 billion, compared to the consensus revenue estimate of $29.0 billion.

Analyst Ratings Changes

A number of research firms have commented on TAK. Zacks Research lowered Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Sanford C. Bernstein raised Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Weiss Ratings cut shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, June 23rd. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK opened at $17.25 on Friday. The stock has a market cap of $55.29 billion, a PE ratio of 44.24 and a beta of -0.07. Takeda Pharmaceutical has a 1 year low of $12.99 and a 1 year high of $18.90. The firm has a fifty day moving average price of $16.25 and a 200-day moving average price of $17.07. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.09 and a quick ratio of 0.60.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, July 30th. The company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.31. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.20%. The company had revenue of $7.50 billion during the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Equities analysts anticipate that Takeda Pharmaceutical will post 1.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sivia Capital Partners LLC bought a new stake in Takeda Pharmaceutical in the 2nd quarter worth approximately $351,000. BNP Paribas Financial Markets grew its holdings in shares of Takeda Pharmaceutical by 1,652.2% in the second quarter. BNP Paribas Financial Markets now owns 11,845 shares of the company’s stock valued at $183,000 after purchasing an additional 11,169 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in shares of Takeda Pharmaceutical in the second quarter valued at $174,000. Cibc World Market Inc. bought a new stake in Takeda Pharmaceutical in the fourth quarter worth $169,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Takeda Pharmaceutical in the fourth quarter worth $166,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.